Literature DB >> 10603373

Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.

R Gopinath1, L E Hanna, V Kumaraswami, V Perumal, V Kavitha, V Vijayasekaran, T B Nutman.   

Abstract

Treatment of patients with patent Wuchereria bancrofti infection results in an acute clinical reaction and peripheral eosinophilia. To investigate the dynamics of the eosinophil response, changes in eosinophil activation and degranulation and plasma levels of eosinophil-active chemokines and cytokines were studied in 15 microfilaremic individuals in south India by sequential blood sampling before and after administration of 300 mg of diethylcarbamazine (DEC). Clinical symptoms occurred within 24 h. Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 days posttreatment, preceding a peak peripheral eosinophil count at day 4. Major basic protein secretion from eosinophils paralleled IL-5 secretion, while levels of eosinophil-derived neurotoxin peaked at day 13 after treatment. Expression of the activation markers HLA-DR and CD25 on eosinophils rose markedly immediately after treatment, while expression of VLA-4 and alpha4beta7 showed an early peak within 24 h and a second peak at day 13. Thus, the posttreatment reactions seen in filarial infections can be divided into an early phase with killing of microfilariae, clinical symptomatology, increases in plasma IL-5 and RANTES levels, and eosinophil activation and degranulation and a later phase with expression of surface integrins on eosinophils, recruitment of eosinophils from the bone marrow to tissues, and clearance of parasite antigen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603373      PMCID: PMC97106          DOI: 10.1128/IAI.68.1.93-99.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Damage to schistosomula of Schistosoma mansoni induced directly by eosinophil major basic protein.

Authors:  A E Butterworth; D L Wassom; G J Gleich; D A Loegering; J R David
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

2.  Eosinophilia and elevated serum levels of eosinophil major basic protein and Charcot-Leyden crystal protein (lysophospholipase) after treatment of patients with Bancroft's filariasis.

Authors:  S J Ackerman; G J Gleich; P F Weller; E A Ottesen
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

3.  Damage to Trichinella spiralis newborn larvae by eosinophil major basic protein.

Authors:  D L Wassom; G J Gleich
Journal:  Am J Trop Med Hyg       Date:  1979-09       Impact factor: 2.345

4.  Comparison of single-dose diethylcarbamazine and ivermectin for treatment of bancroftian filariasis in Papua New Guinea.

Authors:  J Kazura; J Greenberg; R Perry; G Weil; K Day; M Alpers
Journal:  Am J Trop Med Hyg       Date:  1993-12       Impact factor: 2.345

5.  Deposition of eosinophil granule major basic protein onto microfilariae of Onchocerca volvulus in the skin of patients treated with diethylcarbamazine.

Authors:  G M Kephart; G J Gleich; D H Connor; D W Gibson; S J Ackerman
Journal:  Lab Invest       Date:  1984-01       Impact factor: 5.662

6.  Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.

Authors:  A P Limaye; J S Abrams; J E Silver; K Awadzi; H F Francis; E A Ottesen; T B Nutman
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

7.  Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Time and temperature dependent spontaneous release in vitro demands standardized sample processing.

Authors:  C M Reimert; L K Poulsen; C Bindslev-Jensen; A Kharazmi; K Bendtzen
Journal:  J Immunol Methods       Date:  1993-12-03       Impact factor: 2.303

8.  Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.

Authors:  A P Limaye; E A Ottesen; V Kumaraswami; J S Abrams; J Regunathan; V Vijayasekaran; K Jayaraman; T B Nutman
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

9.  RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes.

Authors:  A Rot; M Krieger; T Brunner; S C Bischoff; T J Schall; C A Dahinden
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

10.  Interactions between human eosinophils and schistosomula of Schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence.

Authors:  A E Butterworth; M A Vadas; D L Wassom; A Dessein; M Hogan; B Sherry; G J Gleich; J R David
Journal:  J Exp Med       Date:  1979-12-01       Impact factor: 14.307

View more
  10 in total

1.  Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel.

Authors:  Claus M Reimert; Colin M Fitzsimmons; Sarah Joseph; Joseph K Mwatha; Frances M Jones; Gachuhi Kimani; Karl F Hoffmann; Mark Booth; Narcis B Kabatereine; David W Dunne; Birgitte J Vennervald
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.

Authors:  Jesica A Herrick; Fanny Legrand; Raceline Gounoue; Godwin Nchinda; Céline Montavon; Jean Bopda; Steve Mbickmen Tchana; Bienvenu Etogo Ondigui; Konrad Nguluwe; Michael P Fay; Michelle Makiya; Simon Metenou; Thomas B Nutman; Joseph Kamgno; Amy D Klion
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections.

Authors:  Sasisekhar Bennuru; Grace Maldarelli; V Kumaraswami; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

4.  Localized eosinophil degranulation mediates disease in tropical pulmonary eosinophilia.

Authors:  Laura O'Bryan; Paula Pinkston; V Kumaraswami; V Vijayan; Gordon Yenokida; Helene F Rosenberg; Ronald Crystal; Eric A Ottesen; Thomas B Nutman
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins.

Authors:  Michelle A Makiya; Jesica A Herrick; Paneez Khoury; Calman P Prussin; Thomas B Nutman; Amy D Klion
Journal:  J Immunol Methods       Date:  2014-06-08       Impact factor: 2.303

6.  Eosinophilia: causes and pathobiology in persons with prior exposures in tropical areas with an emphasis on parasitic infections.

Authors:  Yae-Jean Kim; Thomas B Nutman
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.663

7.  Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Authors:  Britt J Andersen; Jessica Kumar; Kurt Curtis; Nelly Sanuku; Samson Satofan; Christopher L King; Peter U Fischer; Gary J Weil
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

8.  Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E.

Authors:  Colin M Fitzsimmons; Sarah Joseph; Frances M Jones; Claus M Reimert; Karl F Hoffmann; Francis Kazibwe; Gachuhi Kimani; Joseph K Mwatha; John H Ouma; Edridah M Tukahebwa; Henry C Kariuki; Birgitte J Vennervald; Narcis B Kabatereine; David W Dunne
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  Diethylcarbamazine and non-diethylcarbamazine related bancroftian granuloma: an immunohistochemical study of eosinophil toxic proteins.

Authors:  Jose Figueredo-Silva; Carmelita Cavalcanti; Luciano Tavares Montenegro; Joaquim Norões; Gerusa Dreyer
Journal:  Int J Biomed Sci       Date:  2010-06

10.  Rapidly boosted Plasma IL-5 induced by treatment of human Schistosomiasis haematobium is dependent on antigen dose, IgE and eosinophils.

Authors:  Shona Wilson; Frances M Jones; Hassan K M Fofana; Aissata Doucouré; Aly Landouré; Gachuhi Kimani; Joseph K Mwatha; Moussa Sacko; Birgitte J Vennervald; David W Dunne
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.